Covid vaccine

  • Russia to produce Covid vaccine with India
    New Delhi, December 21 (PTI): Russian envoy to India Nikolay Kudashev on Monday said Moscow will jointly produce the Sputnik V vaccine for COVID-19 along with New Delhi and it will be manufactured by Indian pharma major Dr Reddy's Laboratories. "We are working very hard to fight COVID-19 together with India, and are now advancing to jointly produce Sputnik V vaccine at the capacities of Dr Reddy's Laboratories to be used in India, Russia and other countries," Kudas
  • Global availability of Covid vaccine for public only by mid-2021: Moody's
    New Delhi, November 25 (IANS): While recent news about the high effectiveness of two coronavirus vaccines is a promising sign in the effort to combat the pandemic, a vaccine for Covid-19 will not be widely distributed before mid-2021, Moodys Investors Service said on Tuesday. "However, these developments do not change the assumption underpinning our economic forecasts that widespread, global availability of the vaccine to the general public is only likely by around mid-202
  • AstraZeneca COVID-19 vaccine can be 90% effective, results show
    LONDON, November 23 (Reuters): AstraZeneca said on Monday its vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen. "This vaccine's efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency," Pascal Soriot, Astra's chief executive, said in a statement. The British drugmaker's preliminar
  • Moderna COVID-19 vaccine to cost govts $25-$37 per dose: CEO
    Berlin, November 23 (IANS): Governments seeking to purchase Moderna's potential Covid-19 vaccine may have to shell out $25 and $37 per dose, depending on the size of the order, the company's CEO Stephane Bancel told German weekly 'Welt am Sonntag' (WamS). Bancel said that the price he quoted was a "fair price" and that the company was not interested in "maximum profit," according to the report on Sunday. The US pharma giant last week said that
  • 'Russia's Sputnik V to cost lower than Pfizer, Moderna's COVID vax'
    Moscow, November 22 (IANS): Russia's Sputnik V vaccine against Covid-19 will cost governments much lower than that of Pfizer's and Moderna's, the official Twitter handle of the world's first registered vaccine against the pandemic said on Sunday. "Translating pharma lingo: the announced price of Pfizer of $19.50 and Moderna of $25-$37 per dose actually means their price of $39 and $50-$74 per person. Two doses are required per person for the Pfizer, Sputnik
  • COVID-19 shots could reach first Americans by mid-December, top health official says
    Reuters US healthcare workers and others recommended for the nation's first COVID-19 inoculations could start getting shots within a day or two of regulatory consent next month, a top official of the government's vaccine development effort said on Sunday. Some 70% of the U.S. population of 330 million would need to be inoculated to achieve "herd" immunity from the virus, a goal the country could achieve by May, according to Dr. Moncef Slaoui, chief scientif
  • Centre plans Covid vax rollout with healthcare workers first, distribution to take a year
    New Delhi, November 1 (IANS): The government has planned to start the distribution of Covid-19 vaccine first to the healthcare workers followed by other groups to be added "sequentially". The distribution drive would take place over a year. For this, the states and union territories would form a three-tier system as per the Centre's directions. "In all likelihood, the Covid-19 vaccine introduction will span over a year with multiple groups being included sequen
  • Vaccine hopes rise as Oxford jab prompts immune response among old as well as young adults
    LONDON, October 26 (Reuters): One of the world's leading COVID-19 experimental vaccines produces an immune response in both young and old adults, raising hopes of a path out of the gloom and economic destruction wrought by the novel coronavirus. The vaccine, developed by the University of Oxford, also triggers lower adverse responses among the elderly, British drug maker AstraZeneca Plc, which is helping manufacture the vaccine, said on Monday. A vaccine that works is se
  • Cong, BJP in K'taka cross swords over vaccine promise
    BENGALURU, OCTOBER 23 (IANS): Taking serious exception to the BJP's poll promise in Bihar of providing free Covid vaccine if the party is voted to power, the Congress in Karnataka termed the saffron party as "Opportunist BJP" while the Karnataka BJP countered it by asking the Congress to "remove hate Modi glasses" and know the difference between governance and poll promise. Launching a scathing attack through his Twitter handle, Leader of the Opposition Sidda
  • Explainer: When will COVID-19 vaccines be generally available in the US?
    Reuter U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) this week disagreed about when a COVID-19 vaccine would become widely available. Trump said on Friday that enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts. WHAT DOES IT MEAN FOR A VACCINE TO BE GENERALLY AVAILABLE? General
  • Covid vax to be available by 'start of next year': Harsh Vardhan
    New Delhi, September 17 (IANS): Union Health Minister Harsh Vardhan on Thursday said that the coronavirus vaccine will be made available in the country by the start of next year. The remarks come at a time when India is recording more than 50 lakh cases and people are awaiting the vaccine with bated breath. "Just like other countries, India is also making efforts. Three vaccines candidates are in different phases. Under Prime Minister's guidance, an expert group is looking
  • AstraZeneca vaccine trial pause a 'wake-up call', says WHO
    ZURICH, September 10 (Reuters): AstraZeneca's pause of an experimental vaccine for the coronavirus after the illness of a participant is a "wake-up call" but should not discourage researchers, the World Health Organization's (WHO) chief scientist said on Thursday. "This is a wake-up call to recognise that there are ups and downs in clinical development and that we have to be prepared," Soumya Swaminathan told a virtual briefing from Geneva. &
  • Covid vaccine likely by year end: AstraZeneca
    New Delhi, September 10 (ANI): AstraZeneca CEO Pascal Soriot on Wednesday expressed hopes that a vaccine against the novel coronavirus developed by the pharmaceutical company would be ready by the end of 2020 or early 2021, despite having to pause clinical trials. Earlier this week, the UK-Swedish company reportedly froze the trials after discovering that one participant was sick with transverse myelitis. This condition results in the inflammation of parts of the spinal cord and may
  • First human trial of Oxford COVID-19 vaccine shows promise
    LONDON, July 20 (Reuters) - An experimental coronavirus vaccine being developed by AstraZeneca and Oxford university was safe and produced an immune response in early-stage clinical trials, data showed on Monday, keeping alive the hope it could be in use by the end of the year.   The vaccine, called AZD1222, has been described by the World Health Organization's chief scientist as the leading candidate in a global race to halt a pandemic that has claimed more than 600,000
  • Early-stage trial data on AstraZeneca COVID-19 vaccine due Monday - Lancet
    LONDON, July 16 (Reuters) - Early-stage human trial data on a vaccine being developed by AstraZeneca and Oxford University will be published on July 20, The Lancet medical journal said on Wednesday.   The vaccine candidate is already in large-scale Phase III human trials to assess whether it can protect against COVID-19, but its developers have yet to report Phase I results which would show whether it is safe and whether or not it induces an immune response.   &ld
  • ICMR aims to launch COVID-19 vaccine by Aug 15
    New Delhi, July 3 (PTI): Aiming to launch an indigenous COVID-19 vaccine by August 15, the Indian Council of Medical Research has written to select medical institutions and hospitals to fast-track clinical trial approvals for the vaccine candidate Covaxin being developed in collaboration with Bharat Biotech.   12 clinical trial sites have been identified at present and the apex health research body has asked the medical institutions and principal investigators to ensure that
  • Bharat Biotech Covid vaccine candidate's human trials from July
    Hyderabad, June 29 (IANS) Leading vaccine maker Bharat Biotech on Monday announced that it has successfully developed Covaxin, India's first vaccine candidate for Covid-19, in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV) and will begin its human trials next month.   The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine was developed and manufactur
  • 'Covid-19 vac not possible soon'
    BY SUMIT SAXENA New Delhi, June 4 (IANS) It is not possible to develop a vaccine for Covid-19 soon, as the RNA virus changes very quickly and this makes it difficult to create a good vaccine, says Claudio Colosio Unimi Professor, Department of Health Sciences University of Milan, Italy.   Claudio as the Director, Occupational Health Unit of the Hospitals Saints Paolo and Carlo of Milano, has been extensively handling the Covid-19 pandemic. When queried about a vaccine sti
  • Pvt-public partnership is working to bring Covid vaccine in India: Dr Harsh Vardhan
    'WE MUST LEARN TO LIVE WITH THE VIRUS EVEN AS WE CONTINUE OUR SOCIO-ECONOMIC ACTIVITIES'   New Delhi, May 28 (IANS) The government's point man on the gravest health emergency confronting the world and India is Dr Harsh Vardhan, our very own Health Minister, a Chandni Chowk MP. A doctor himself and in the main an Otorhinolaryngologist, he has risen from a doctor to a well-regarded politician. Extremely soft-spoken, he has been a minister in the Delhi government and
  • COVID-19 here to stay till 2021, aggressive testing needed to curb its spread: Health experts
    New Delhi, May 27 (PTI) Global health experts on Wednesday said novel coronavirus is here to stay for more than a year and called for aggressive testing to prevent its spread.   In an interaction with Congress leader Rahul Gandhi, health experts Professor Ashish Jha and Professor Johan Giesecke talked about the COVID-19 pandemic as part of the series being aired on Congress social media channels.   While Jha exuded confidence that a vaccine will be available in a